Wu Kunzhe, Yu Beibei, Li Di, Tian Yangyang, Liu Yan, Jiang Jinlan
Department of Scientific Research Center, China-Japan Union Hospital of Jilin University, Changchun, China.
Department of Anesthesiology, China-Japan Union Hospital of Jilin University, Changchun, China.
Front Oncol. 2022 Feb 15;12:805978. doi: 10.3389/fonc.2022.805978. eCollection 2022.
Osteosarcoma (OS) is the most common primary bone tumor in children and young people. Traditional surgical excision combined with chemotherapy presents many limitations, such as resistance and systemic side effects of chemotherapy drugs, postoperative recurrence, and bone defects. Given these limitations, novel therapeutic modalities for OS treatment using nanometer-sized platform-based chemotherapeutic delivery have emerged as a promising alternative therapy. This form of therapy offers multiple advantages, such as accurate delivery of the drug to the tumor site and repair of limited bone defects after tumor resection. In this review, we briefly summarize nanoplatforms, including liposomes, polymeric nanoparticles, inorganic nanoparticles, nanomicelles, dendrimers, nanocapsules, and exosomes. The essential shortcomings involved in these nanoplatforms, such as poor stability, immunogenicity, insufficient circulation, and drug leakage are also discussed, and related solutions are briefly proposed. Finally, the application prospects of nanoplatforms in the treatment of OS are discussed.
骨肉瘤（OS）是儿童和青少年中最常见的原发性骨肿瘤。传统的手术切除联合化疗存在许多局限性，如化疗药物的耐药性和全身副作用、术后复发以及骨缺损。鉴于这些局限性，使用基于纳米级平台的化疗递送治疗骨肉瘤的新型治疗方法已成为一种有前景的替代疗法。这种治疗形式具有多种优势，如将药物准确递送至肿瘤部位以及在肿瘤切除后修复有限的骨缺损。在本综述中，我们简要总结了纳米平台，包括脂质体、聚合物纳米颗粒、无机纳米颗粒、纳米胶束、树枝状大分子、纳米胶囊和外泌体。还讨论了这些纳米平台所涉及的主要缺点，如稳定性差、免疫原性、循环不足和药物泄漏，并简要提出了相关解决方案。最后，讨论了纳米平台在骨肉瘤治疗中的应用前景。
